bluebird bio
BLUE
#9803
Rank
NZ$84.49 M
Marketcap
NZ$8.63
Share price
0.00%
Change (1 day)
-75.12%
Change (1 year)

Revenue for bluebird bio (BLUE)

Revenue in 2025 (TTM): NZ$0.17 Billion

According to bluebird bio 's latest financial reports the company's current revenue (TTM ) is NZ$0.18 Billion. In 2024 the company made a revenue of NZ$0.14 Billion an increase over the revenue in the year 2023 that were of NZ$46.64 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for bluebird bio from 2012 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) NZ$0.17 B20.92%
2024 NZ$0.14 B218.59%
2023 NZ$46.64 M723.06%
2022 NZ$5.66 M-110.4%
2021 -NZ$54.5 Million-115.68%
2020 NZ$0.34 B423.87%
2019 NZ$66.33 M-18.48%
2018 NZ$81.36 M63.12%
2017 NZ$49.88 M461.39%
2016 NZ$8.88 M-56.81%
2015 NZ$20.57 M-36.59%
2014 NZ$32.44 M32.11%
2013 NZ$24.55 M5841.94%
2012 NZ$0.41 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
BioMarin Pharmaceutical
BMRN
NZ$5.37 B 2,876.55%๐Ÿ‡บ๐Ÿ‡ธ USA
Acceleron Pharma
XLRN
NZ$0.19 B 8.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
NZ$82.51 B 45,620.93%๐Ÿ‡ซ๐Ÿ‡ท France
Sangamo Therapeutics
SGMO
NZ$57.07 M-68.37%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
NZ$111.52 B 61,696.51%๐Ÿ‡บ๐Ÿ‡ธ USA
GlycoMimetics
GLYC
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA